Viewing nowCombinationOlmesartan Medoxomil/Amlo-dipine 5/40 mg Tablets
Olmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
HLB Pharmaceuticals Co., Ltd.

MFDS item code 202000346 · Approved 2020.01.21 · Insurance code 647304450
Treatment of essential hypertension not controlled by monotherapy
This medication is used in patients with essential hypertension who find it difficult to control blood pressure with either amlodipine or olmesartan medoxomil alone. It effectively lowers blood pressure and helps reduce the risk of cardiovascular diseases.
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. This medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Do not administer to the following patients under Precautions for Use.) Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, take the patient's renal or cardiac function and comorbidities into account. Blood pressure should be monitored closely and more frequently in elderly patients.
The safety and efficacy have not been established in pediatric patients under 18 years of age.
This medication can cause serious damage to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. It should not be taken if there is hypersensitivity to any of its components, or if the patient is pregnant or breastfeeding, has severe liver disease, aortic stenosis, bile duct obstruction, is undergoing kidney dialysis, is in a state of shock, or has certain types of diabetes. In patients who are volume or salt-depleted, hypotension may occur, so their condition should be closely monitored at the start of treatment, and appropriate measures should be taken if symptoms of hypotension arise. Acute hypotension may rarely occur due to its vasodilatory effects, so particular caution is needed in patients with aortic stenosis. In patients with severe heart disease, congestive heart failure, reduced kidney function, or impaired liver function, this medication should be used with caution. Side effects such as dizziness, headache, hypotension, orthostatic hypotension, edema, gastrointestinal disturbances, and rash may occur; if any unusual symptoms appear, consultation with a physician is advised. It is advisable for pregnant or breastfeeding women to avoid this medication, and if breastfeeding, they should either stop breastfeeding or discontinue the medication. Safety and efficacy have not been established in children under the age of 18, thus it is not recommended for this age group. Elderly patients may be more sensitive to this medication due to reduced liver, kidney, or heart function, hence starting with a low dose and careful monitoring is recommended. In case of overdose, hypotension and decreased cardiac function may occur, so immediate medical treatment should be sought. Taking this medication with grapefruit juice may excessively enhance the blood pressure-lowering effect, so it is advisable not to take them together. When combined with other medications, the potential for interactions exists, thus it is crucial to consult with a physician or pharmacist, especially with potassium-sparing diuretics, lithium, and non-steroidal anti-inflammatory drugs. Keep the medication out of the reach of children and store it in a tightly sealed container, avoiding direct sunlight and moisture.
Not everyone experiences these, and they can vary from person to person.
This medication can be sensitive to air and moisture, so it should be stored in a tightly sealed container. To maintain the efficacy of the medication, it is best to store it at room temperature, specifically between 1 to 30 degrees Celsius.
Pale yellow round film-coated tablets
28 tablets/box [14 tablets/PTP×2]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
HLB Pharmaceuticals Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.